drugset / Trial / NCT07312721

Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis

NCT07312721

Phase 4 Completed 752 enrolled Azfar Farogh
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized controlled trial is designed to compare the efficacy of standard triple therapy versus bismuth-based quadruple therapy for the eradication of Helicobacter pylori-induced gastritis. The study is being conducted at Shahida Islam Medical College, Lodhran, Pakistan. Adult patients with confirmed H. pylori infection are randomly allocated to receive either a 14-day triple therapy regimen or a 14-day bismuth-based quadruple therapy regimen. Eradication of H. pylori is assessed six weeks after completion of treatment using stool antigen testing. The primary outcome measure is the proportion of patients achieving successful eradication of H. pylori.

Timeline

Start
2024-01-05
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Subject Bismuth subsalicylate Small molecule
Subject Clarithromycin Small molecule 500 mg
Subject Metronidazole Small molecule 400 mg
Subject Tetracycline Unknown 500 mg
Background Omeprazole Other / unclassified 40 mg